Mail to a Friend
Rate      

Biofrontera Appeals PTAB, Seeks Cancellation of Dusa’s Patent



2021-12-08 02:09:54 Health and Fitness

forpressrelease
376


Biofrontera AG has approached U.S.Patent Trial and Appeal Board (PTAB) for its petition to cancel a patent owned by Sun Pharmaceutical Industries Limited’s owned Dusa Pharmaceuticals, Inc. Both the companies have treatments for a pre-cancerous skin condition actinic keratosis. The plaintiff is claiming that the defendant is infringing the patent that covers “a common off-label use” of the therapy.

User :- TMReady

Email :-rakhi.tushir@sagaciousresearch.com

Url :- https://ipnewsshots.com/biofrontera-appeals-ptab-seeks-cancellation-of-dusas-patent/


forpressrelease



Related Post

Advertisement